| Assessment Status | Rapid Review Complete |
| HTA ID | 23018 |
| Drug | Fostemsavir |
| Brand | Rukobia ® |
| Indication | Fostemsavir (Rukobia ®) in combination with other antiretrovirals, is indicated for the treatment of adults with multidrug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen. |
| Assessment Process | |
| Rapid review commissioned | 27/03/2023 |
| Rapid review completed | 20/04/2023 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of fostemsavir compared with the current standard of care, on the basis of the proposed price. * |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations. December 2024
